By Ria Kakkad (Drug Target Review)2023-04-11T10:00:40
New research from Cincinnati Children’s Hospital Medical Center suggests blocking IL-22 and IL-1R could offer a promising IBD treatment.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-03-25T15:00:00 2026-03-25T16:00:00
Sponsored by Yokogawa
2023-02-03T13:56:13
Sponsored by Leica Microsystems
2023-02-02T11:05:15
Sponsored by Cell Signaling Technology
2023-07-04T09:00:08
Sponsored by SB Drug Discovery
2023-02-16T14:53:10
Sponsored by Cell Signaling Technology
2024-01-19T07:40:55
Sponsored by Euretos
Site powered by Webvision Cloud